• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    Alcami

    Aphena Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Federal Equipment Company

    Adare Pharma Solutions

    Emergent BioSolutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Opportunities to Lower Drug Prices and Improve Affordability

    From creation (manufacturing) to consumption (patient)

    Opportunities to Lower Drug Prices and Improve Affordability
    Related CONTENT
    • Reshaping the Pharmaceutical Supply Chain
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    Girish Malhotra, Contributing Editor05.08.18
    Since the beginning of 2018, the push to curb ever increasing drug prices has picked up steam. Two recent announcements1-4 in particular are what I consider to be “constructive destructionist”5 in nature and if successful, could have a lasting impact and game changing influence on the pharma landscape.

    Leading up to these announcements, there has been a lot of talk and proposed legislation to curtail drug costs. However, we have to accept the fact that any change being proposed by legislators or put on the ballot box is not going to come to fruition. The pharma lobby has too big of an influence on the electability of legislators who want to stay in office for as long as possible. This relationship between the pharma industry and legislators has not worked out in favor of the constituents who want justifiably lower drug prices.

    The recent initiatives are worth taking a look at because as I mentioned, each presents a possible game changing opportunity to improve drug affordability while at the same time improving product quality, revenues and profits for the pharma industry. In the U.S., drugs are acquired through two major systems: Veteran’s Affairs for military veterans and for the rest of the country through mutually subsidized healthcare systems that includes Medicare. Veteran’s Affairs along with selected Health Systems (VAH) and Amazon, Berkshire Hathaway and JPMorgan2-4 (ABM) are set to cause a stir to the existing mutually subsidized system when it comes to their employees. The partnership between these organizations could be the start of a revolution against ever increasing drug prices.

    Veteran’s Affairs
    There are about seven million participants in the Veteran’s Affair (VA) system. Some of us may not know it but the VA has its own methods for acquiring drugs at discounted prices.6 Its drug acquisition plan is unique and most likely is not entertained by pharmaceutical companies because the number of drugs offered are restricted and pharma and supply chain profits are lowered. However, pharma companies have acquiesced to avoid the wrath of the U.S. government and the country. The following guidelines have to be followed: 

    “Unlike Medicare, in which beneficiaries can choose drug plans, each with its own formulary, the VA offers no choice. Serving as the sole purchaser of drugs, the VA maintains a single national formulary that physicians must follow. The VA formulary is created through access restrictions on drugs. For drugs to be covered on the formulary, their makers must list all of their drugs on the Federal Supply Schedule (FSS) for federal purchasers at the price given to the most-favored nonfederal customer under comparable terms and conditions.

    Additionally, drug makers must offer the VA a price lower than a statutory federal price ceiling (FPC), which mandates a discount of at least 24 percent off the non-federal average manufacturer price (NFAMP), with a rebate if price increases exceed inflation.”

    Even with the VA’s restrictive purchasing program, the February 2018 announcement1 presents generic drug producers with a way to capitalize on an opportunity to expand their markets—other Mutually Subsidized and Medicare systems—and increase profits and revenues. Since the healthcare systems are going to be directly working with the manufacturers, it is a unique opportunity for them to capitalize on the values of economies of scale and innovative manufacturing technologies.7,8

    Mutually subsidized systems
    VAH and ABM alliances9 should use reverse calculations10 to encourage manufacturing companies to innovate. Economies of scale and “what if” analysis can be used to improve manufacturing processes. The upside of the effort is going to be higher revenues, higher profits and lower drug costs. FDA and other regulators will have to be open minded and proactive to make sure innovative manufacturing practices are adopted on a timely basis and commercialized.11,12    

    Figure 1 is a schematic of the supply chain that is applicable to patients in Medicare and mutually subsidized healthcare systems. 


    Figure 1.


    Pharmacy benefit managers (PBM),13 or middlemen, facilitate the distribution of drugs to most outside the VA system. Manufacturing and costs of APIs and their formulations are simple to understand.10,14 However, under the current system pricing from formulations to the patients becomes murky and complex. The mystery is being slowly unraveled.15-19 States are also taking steps to contain rising prices.20,21 

    PBMs have made every attempt to make sure that the cost details are not readily available and the patients pay the highest drug prices. UnitedHealth22 has announced a possible peak in the PBM “black box.” However, until the beans of this initiative are counted and everything is black and white, it is too early to grasp the impact.   
      
    It is interesting to note that PBMs block the direct import of drugs by the patients from, for example, Canada and other countries, but the same drugs are imported and sold at a significantly higher price in the U.S. The explanation given is related to the safety of the drug. This also could be considered an artificial way to keep prices up by using scare tactics. Uniform global drug standards will greatly help the situation but they would be a challenge to establish.

    From drug price information collected in India and in U.S.14 (with regular insurance, Medicare and NO insurance) one can easily see the reasons why PBMs have discouraged the ABM alliance2 to take a peak in the “black box.” Most can conjecture that PBMs do not want anyone to negotiate and jeopardize their profits. Sood etal16 and Grant17 have done an excellent review of the PBM price structure. Price multiples of between 100-1500 times from manufacturing to patients,14,16 should be an eye opener for the negotiators in the VA and ABM alliance. As I mentioned earlier, economies of scale and better technologies can significantly lower these multiples.

    Drug price reduction opportunities
    Using Panel B for the money flow16 illustration, it is interesting to note how a $18 drug gets to the patient in the current system and sells for $100.


    Panel B.16


    Using sound principles of economics, chemical engineering, chemistry, economies of scale and good manufacturing practices, a 20% reduction in manufactured cost will translate to about $80 to the patient if no improvements are done to the current PBM supply chain “black box.” Twenty-percent or better cost reduction in the supply chain should not be considered out of reach. Combined cost reductions in manufacturing and the supply chain would mean that a current $100 drug would cost about $65 to the patient. I am sure a $35 cost reduction is worth the effort. Twenty-percent cost reductions in manufacturing and in the supply chain each are not out of the realm of possibility. Effort would be needed but everyone along the drug product supply chain from creation (manufacturing) to consumption (patient) will benefit financially.

    Business model change
    Accelerated 2018 chatter is not going to let up. It seems that the pressure to make drugs affordable or lower drug prices will continuously increase. Dan Akerson, former chief executive of General Motors, said it well when he said, “If you don’t attack your own business model, trust me, somebody else will.”

    So far pharma companies and PBMs have stuck with their models of creating new drugs and along with PBMs selling them at the highest price participants can afford in mutually subsidized systems. Essentially no effort has been made to improve their methods to lower drug costs. In the last few years big pharma companies have relied on orphan drugs or marginally better drugs to improve their revenues and profits. These are not going to sustain major pharma companies for the long haul.

    Since generic drugs in the U.S., which represent an ever-increasing need, are distributed through PBMs in our mutually subsidized healthcare systems, even they are priced at the highest level (see Table 1). We have to recognize that Pharma/PBMs major customer base is dependent on affordable drugs. The current Pharma/PBM business model has to change. It is time. 

    There is a need and it seems that PBMs and associated companies are trying to cater to shareholders25 rather than the patients who are the basis of their existence. With the success of the VAH and ABM Alliance we could see the spread of drug price reductions. The pace could accelerate moving forward now that  “the cat is out of the bag.” The question is how the pharma industry and PBMs are going to participate for everyone’s benefit. My conjecture is outliers will cause a change and it will happen sooner than expected. 


    Table 1.


    References
    1. Leading U.S. Health Systems Announce Plans to Develop a Not-for-Profit Generic Drug Company, www.businesswire.com, Accesses March 1, 2018.
    2. Triple Threat: Amazon, Berkshire, JPMorgan Rattle Health-Care Firms, The Wall Street Journal, January 30, 2018, Accessed January 31, 2018.
    3. If Amazon And Buffett Lift Veil On Health Prices, Insurers Are In Trouble, Forbes.com, January 31, 2018, Accessed January 31, 2018.
    4. JPMorgan to Banking Clients: Joint Health-Care Venture Is No Threat, WSJ.COM, February 4, 2018, Accessed February 4, 2018.
    5. Creative destruction: https://en.wikipedia.org/wiki/Creative destruction Accessed January 31, 2018.
    6. D’Angelo, Greg: The VA Drug Pricing Model: What Senators Should Know, The Heritage Foundation, April 11, 2007, Accessed March 5, 2018.
    7. Malhotra, Girish:  Chemical Process Simplification: Improving Productivity and Sustainability John Wiley & Sons, February 2011.
    8. Malhotra, Girish: Innovation In Pharmaceuticals: What Would It Take & Who is Responsible?, Profitability through Simplicity, November 28, 2017, Accessed March 5, 2018.
    9. Malhotra, Girish: Could Amazon (A), Berkshire Hathaway (B) and J.P. Morgan Chase (M) be the Anti-Ballistic Missile (ABM) Needed to Control/Curb Rising Healthcare Costs? Profitability through Simplicity, February 9, 2018, Accessed February 27, 2018.
    10. Malhotra, Girish: A Blueprint for Improved Pharma Competitiveness, Contract Pharma, September 8, 2014, Accessed February 28, 2018.
    11. Malhotra, Girish: Can the Review and Approval Process for ANDA at USFDA be Reduced from Ten Months to Three Months? Profitability through Simplicity, March 25, 2017, Accessed March 5, 2018.
    12. Malhotra, Girish: ANDA (Abbreviated New Drug Application) / NDA (New Drug Applications) Filing Simplification: Road Maps are a Must. Profitability through Simplicity, May 11, 2017, Accessed March 5, 2018.
    13. What Is a Pharmacy Benefit Manager (PBM) And How Does A PBM Impact The Pharmacy Benefits Ecosystem?, www.truveris.com, August 15, 2017, Accessed February 27, 2018.
    14. Malhotra, Girish: Comparison of Drugs Prices: US vs. India; Their Manufacturing Costs & Opportunities to Improve Affordability, Profitability through Simplicity, January 18, 2018.
    15. Why Your Pharmacist Can’t Tell You That $20 Prescription Could cost Only $8, The New York Times, Accessed February 26, 2018.
    16. Sood, N; Shih, T; Van Nuys, K; Goldman, D; The Flow of Money Through the Pharmaceutical Distribution System, June 14, 2017, http://healthpolicy.usc.edu/Flow_of_Money_Through_the_Pharmaceutical_Distribution_System.aspx, Accessed March 1, 2018.
    17. Grant, Charley, Hidden Profits In the Prescription Drug Supply Chain, The Wall Street Journal, February 26, 2018, Accessed February 27, 2018.
    18. Profits Are Hidden in the Prescription Drug Supply Chain, The Wall Street Journal, February 26, 2018, Accessed February 27, 2018.
    19. Grant, Charley, White House Eyes Role of Middlemen in Drug Price Fight, The Wall Street Journal, February 12, 2018, Accessed March 1, 2018.
    20. On Drug Pricing, States Step In Where Washington Fails, The New York Times, February 27, 2018, Accessed February 27, 2018.
    21. House Bill 4005, 79Th Oregon Legislative Assembly -2018, Price and Cost of Prescription Drugs, February 26, 2018, Accessed March 5, 2018.
    22. UnitedHealth Will Pass Drug Rebates Directly to Some Consumers, The Wall Street Journal, March 6, 2018, Accessed March 6, 2018.
    23. Private conversation with Mr. Jack Harding Jr., Harding & Harding Associates, North Canton, OH March 1, 2018.
    24. Private communication with a Pharmacist at a leading pharmacy, February 26, 2018.
    25. Herper, Matthew: Cigna's $54 Billion Purchase Of Express Scripts Could Upend The Prescription Drug Market, Forbes.com, March 8, 2018, Accessed March 9, 2018.


    Girish Malhotra
    Contributing Editor

    Girish Malhotra, president and founder of EPCOT International, has more than 45 years of industrial experience in pharmaceuticals, specialty, custom, fine chemicals, coatings, resins and polymers, additives in manufacturing, process and technology development and business development. girish@epcotint.com; Tel: 216-223-8763.
    Related Searches
    • quality
    • fda
    • contract pharma
    • generic
    Suggested For You
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    BMS Expands Cell Therapy Manufacturing Capabilities BMS Expands Cell Therapy Manufacturing Capabilities
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program Cryoport Launches ESG Program
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    Antares Vision Agrees to Acquire rfXcel Corporation Antares Vision Agrees to Acquire rfXcel Corporation
    RedHill and Cosmo Strengthen Manufacturing Agreements RedHill and Cosmo Strengthen Manufacturing Agreements
    Novavax, SK Bioscience Expand Vax Pact Novavax, SK Bioscience Expand Vax Pact
    J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate
    Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership
    Delivering Custom Client Solutions Delivering Custom Client Solutions
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement

    Related Pharma Beat

    • The Changing Approach to Design: Five Ways to Achieve Warp Speed

      The Changing Approach to Design: Five Ways to Achieve Warp Speed

      Revisiting facility design and construction based on today’s biopharmaceutical industry needs.
      Jarrod Wrampe, Contributing Editor 10.14.20

    • The “Three Cs” of C(D)MO Selection

      The “Three Cs” of C(D)MO Selection

      Plus, what does it take for contract organizations to fall in the “Goldilocks” zone for pharmaceutical companies?
      Valdas Jurkauskas, Ph.D., Akebia Therapeutics 07.15.20

    • Supply Chain
      Supply Chain Disruptions

      Supply Chain Disruptions

      The implications of Sandoz’ recent recalls.
      Ed Silverman, Guest Columnist 10.15.19


    • cGMP Manufacture
      The Good, The Bad, and The Ugly Complexities of Pharmaceutical Manufacturing

      The Good, The Bad, and The Ugly Complexities of Pharmaceutical Manufacturing

      What does it really take to develop, design, scale-up, commercialize and manage continuous processes?
      Girish Malhotra, Contributing Editor 06.12.18

    • Healthcare Costs Run Rampant

      Healthcare Costs Run Rampant

      Could Amazon, Berkshire Hathaway and J.P. Morgan Chase be the anti-ballistic missile needed to control and curb rising hea
      Girish Malhotra, Contributing Editor 03.09.18

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17


    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17

    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17


    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Can Greens Cure Cancer?

      Long touted for its health properties, broccoli is being studied for its potential curative effects in cancer
      Adele Graham-King, Contributing Editor 07.12.16


    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16

    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Where is The Silver Bullet for Alzheimer’s?

      There continues to be a lack of progress with regards to a cure for AD.
      Adele Graham-King, Contributing Editor 03.09.16

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login